Hypertrophic cardiomyopathy (HCM) is defined by ventricular hypertrophy. However, the broader phenotype includes abnormal cardiomyocyte orientation (disarray), myocardial ischaemia and electrical abnormalities, which seem to manifest before overt hypertrophy. With advances in cascade genetic testing and novel therapeutic agents, the detection of subclinical HCM is a rapidly emerging priority. In this context, we outline the role of novel biomarkers, particularly quantitative perfusion and diffusion tensor MRI.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 per month
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Ommen, S. R. et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. Circulation 142, e558–e631 (2020).
Garcia-Canadilla, P. et al. Myoarchitectural disarray of hypertrophic cardiomyopathy begins pre-birth. J. Anat. 235, 962–976 (2019).
Hughes, R. K. et al. Myocardial perfusion defects in hypertrophic cardiomyopathy mutation carriers. J. Am. Heart Assoc. 10, e020227 (2021).
Lehman, S. J., Crocini, C. & Leinwand, L. A. Targeting the sarcomere in inherited cardiomyopathies. Nat. Rev. Cardiol. 19, 353–363 (2022).
Ariga, R. et al. Identification of myocardial disarray in patients with hypertrophic cardiomyopathy and ventricular arrhythmias. J. Am. Coll. Cardiol. 73, 2493–2502 (2019).
Captur, G. et al. Identification of a multiplex biomarker panel for hypertrophic cardiomyopathy using quantitative proteomics and machine learning. Mol. Cell. Proteomics 19, 114–127 (2020).
Lorenzini, M. et al. Penetrance of hypertrophic cardiomyopathy in sarcomere protein mutation carriers. J. Am. Coll. Cardiol. 76, 550–559 (2020).
Rudy, Y. Noninvasive mapping of repolarization with electrocardiographic imaging. J. Am. Heart Assoc. 10, e021396 (2021).
Ho, C. Y. et al. The burden of early phenotypes and the influence of wall thickness in hypertrophic cardiomyopathy mutation carriers: findings from the HCMNet study. JAMA Cardiol. 2, 419–428 (2017).
Raman, B. et al. Association between sarcomeric variants in hypertrophic cardiomyopathy and myocardial oxygenation: insights from a novel oxygen-sensitive cardiovascular magnetic resonance approach. Circulation 144, 1656–1658 (2021).
G.J. is funded by a British Heart Foundation Clinical Research Training Fellowship (FS/CRTF/21/2469). J.C.M. receives funding directly and indirectly from the NIHR Biomedical Research Centres at University College London Hospitals and Barts Health NHS Trusts. L.R.L. is supported by a Medical Research Council (MRC) UK Research and Innovation (UKRI) Clinical Academic Research Partnership (CARP) award (MR/T005181/1).
J.C.M is the chief executive officer of Mycardium AI and has served on advisory boards for Genzyme and Sanofi. L.R.L. has received consulting/speaker fees from Bristol Myers Squibb, NovoNordisk and Sanofi, and is funded by a project grant from Bristol Myers Squibb. G.J. declares no competing interests.
Rights and permissions
About this article
Cite this article
Joy, G., Moon, J.C. & Lopes, L.R. Detection of subclinical hypertrophic cardiomyopathy. Nat Rev Cardiol (2023). https://doi.org/10.1038/s41569-023-00853-7